Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial
Official title:
Determining the Effectiveness of Nebulized Morphine in Treating Dyspnea in Advanced Idiopathic Pulmonary Fibrosis
"Determination of the effectiveness of nebulized morphine in the treatment of dyspnea in patients with advanced idiopathic pulmonary fibrosis"
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05119972 -
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
|
Phase 1/Phase 2 | |
| Completed |
NCT01718990 -
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
|
||
| Completed |
NCT00162760 -
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
|
Phase 2 | |
| Terminated |
NCT04589260 -
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Completed |
NCT04069143 -
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
|
Phase 1 | |
| Completed |
NCT03050255 -
Short-term Effects of Supplemental Oxygen in Patients With IPF
|
N/A | |
| Terminated |
NCT02013700 -
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
|
Phase 1 | |
| Recruiting |
NCT04598919 -
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03981094 -
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02758808 -
Pulmonary Fibrosis Foundation Patient Registry
|
||
| Not yet recruiting |
NCT05387785 -
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Recruiting |
NCT05938920 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02538536 -
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT01371305 -
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Withdrawn |
NCT03720483 -
Inhaled NAC in Treatment of IPF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03478553 -
The Genetics of Pulmonary Fibrosis
|
||
| Recruiting |
NCT05975983 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03650075 -
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03832946 -
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02874989 -
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
|
Phase 1 |